<div id="readability-page-1"><div>(Alliance News) - Hutchmed China Ltd on Wednesday said it has begun the global phase one clinical development programme for its targeted cancer therapy for patients with solid tumours.The global commercial-stage biopharmaceutical company, headquartered in Hong Kong, said the first in-human trial is for HMPL-A251, an antibody-targeted therapy conjugate. The programme, which has study sites in the US and China, kicked off with the first patient receiving the first dose on Tuesday. HMPL-A251 is the first clinical-stage candidate derived from Hutchmed's next-generation ATTC platform, the company said. ATTCs combine chemotherapy and targeted therapies. The platform enables the development of drug candidates for diverse cancer types, Hutchmed said. The study will evaluate HMPL-A251 in adult patients with unresectable, or not surgically removable, advanced or metastatic HER2-expressing solid tumours. HER2 is a receptor protein, which in cancer cells promotes excessive cell growth.The study is divided into two parts: phase one is dose escalation, and phase 2a is dose expansion and optimisation. In preclinical studies, HMPL-A251, which links the antibody and the payload, &#34;exhibited superior anti-tumour efficacy and tolerability&#34;, compared to co-administration, Hutchmed said. Shares in Hutchmed China rose 1.0% to 202.00 pence on Wednesday afternoon in London. By Roya Shahidi, Alliance News reporterComments and questions to newsroom@alliancenews.comCopyright 2025 Alliance News Ltd. All Rights Reserved.</div></div>

和黄医药

和黄医药已启动 HMPL-A251 的全球一期临床开发项目，这是一种针对实体肿瘤的靶向癌症治疗。该项目包括美国和中国的研究地点，首位患者已接受治疗。HMPL-A251 源自和黄医药的 ATTC 平台，结合了化疗和靶向治疗。该研究将评估该疗法在 HER2 表达肿瘤中的疗效。公告发布后，和黄医药的股价上涨了 1.0%

和黄医药启动 ATTC 候选药物的临床开发